Table 1.
Characteristics of the selected PDX models.
| PDX ID | DDP sensitivity | olaparib sensitivity | TP53 status | BRCA1 status | Site of tumor transplant |
|---|---|---|---|---|---|
| MNHOC#22 | +++ | -* | mut | mut | i.p. |
| MNHOC#266 | +++ | -* | mut | mut | i.p. |
| MNHOC#218Ola | +++ | -& | mut | mut | s.c. |
| MNHOC#124 | +++ | -$ | mut | wt | s.c. |
| MNHOC#239 | ++ | -$ | mut | wt | s.c. |
| MNHOC#316DDP | - | -$ | mut | wt | i.p. |
+++ very sensitive, ++ sensitive, − resistant, * intrinsically resistant (whose mechanisms are under study), & acquired resistance,
$ resistant due to the presence of a wt BRCA1, DDP cisplatin, i.p. intraperitoneally, s.c. subcutaneously.